Login to Your Account



Illuminating Uveitis; Lux Seeks Luveniq Approval in U.S., Europe

By Jennifer Boggs


Friday, February 5, 2010
With simultaneous filings for uveitis drug Luveniq in the U.S. and Europe, Lux Biosciences Inc. has done what few small, private biotechs have managed in today's tough economy: get a drug to market without the help of public funding or a big pharma partner. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription